Search
Search Menu

Thomas Steckler

Thomas Steckler, MD, is Associate Director, Bioresearch Quality & Compliance, Preclinical Quality Risk Management and global Bioresearch Quality & Compliance Lead Animal Welfare, Janssen Pharmaceutica NV, Belgium. He studied Medicine at the Free University of Berlin, Germany and habilitated in Biological Psychology at the Heinrich-Heine University, …

Read more

Renza Roncarati

Renza Roncarati studied biology at the University of Bologna in Italy and obtained her PhD from the Max-Planck-Institute for Plant Breeding Research and the University of Cologne in Germany. Subsequently, she was a Postdoctoral Fellow at the Department of Medical Genetics and Virology of the University of …

Read more

Paul Moser

Paul trained as a pharmacologist in the UK, first in Bristol, then in Bath for his Ph.D., specialising in chronopharmacology. He has spent over 30 years in the pharma industry in both big and medium pharma companies, biotech and also in contract research. After a few …

Read more

Rita Balice-Gordon

Rita Balice-Gordon, Ph.D., is the CSO of Muna Therapeutics, a newly formed Neurology focused biotech company working on developing novel therapeutics for neurodegenerative diseases. She is working with Anders Hinsby, Jakob Busch-Petersen, Joachim Vilstrup, Simon Glerup Pedersen and the team at Novo Ventures to transform cutting-edge …

Read more

Phil Skolnick

Dr. Skolnick is the Chief Scientific Officer at Opiant Pharmaceuticals, Inc. Prior to joining Opiant, he was the Director, Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse, NIH (2010-2017).  He served as Chief Scientific Officer (2001-2009) and President (2007-2009) of DOV Pharmaceutical, …

Read more

Valentina Vengeliene

Valentina obtained a PhD in pharmacology from Heidelberg University in 2005, based on her research done at the Central Institute of Mental Health in Mannheim, Germany. Following her PhD, she continued as a scientist at the Central Institute of Mental Health, focusing on addiction. In particular, …

Read more

C. Glenn Begley

M.B., B.S., Ph.D., F.R.A.C.P., F.R.C.P.A., F.R.C.Path., F.A.H.M.S. Dr Begley is the inaugural CEO of BioCurate, a joint initiative of Monash and Melbourne Universities and created to provide commercial focus in the early phases of drug development. He served as Chief Scientific Officer at Akriveia Therapeutics, California (2016-2027) …

Read more

Dan Deaver

During my academic career I fostered important research collaborations both within and outside the university related to drug development. These efforts required the generation of robust data packages. In the late 1980s, I worked closely with the Upjohn Company during their development of recombinant bovine somatotropin. …

Read more

Rob Miller

Rob Miller has 17 years of biopharma commercial experience with Lilly, Abbott and AbbVie that provides the PAASP US team with an in-depth understanding of how future PAASP biopharma customers develop risk-adjusted valuations for both internal and external innovation:     •New product commercial development and for over …

Read more

Patricia Kabitzke

I obtained my PhD from the City University of New York in Neuroscience, followed by a Postdoctoral fellowship at the Columbia university in New York. During the latter, I completed two projects: 1.) I investigated the neural mechanisms underlying the innate fear response early in life, …

Read more

Scroll Up